

# Daniela Gallo

## List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/3314041/publications.pdf](https://exaly.com/author-pdf/3314041/publications.pdf)

Version: 2025-02-01

63

PR articles

1,922

PR citations

165620

27

PR h-index

225880

42

g-index

66

documents

2110

doc citations

179003

28

h-index

4348

citing authors

#	ARTICLE	IF	PR CITATIONS
1	The interaction of $\beta$ -arrestin1 with talin1 driven by endothelin A receptor as a feature of $\beta$ 5 $\beta$ 1 integrin activation in high-grade serous ovarian cancer. <i>Cell Death and Disease</i> , 2023, 14, .	8.7	10
2	Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2023, 15, 2361.	4.0	2
3	Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	11.5	29
4	Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	5.6	36
5	What's beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study. <i>Cancers</i> , 2022, 14, 4588.	4.0	3
6	Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go. <i>Journal of Personalized Medicine</i> , 2021, 11, 216.	2.6	85
7	In search for biomarkers and potential drug targets for uterine serous endometrial cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1647-1658.	2.4	10
8	Stat1 confers sensitivity to radiation in cervical cancer cells by controlling Parp1 levels: a new perspective for Parp1 inhibition. <i>Cell Death and Disease</i> , 2021, 12, .	8.7	20
9	Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study. <i>Cancers</i> , 2021, 13, 5152.	4.0	17
10	KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, .	11.5	32
11	Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2020, 12, 966.	4.0	36
12	Estrogens Counteract Platinum-Chemosensitivity by Modifying the Subcellular Localization of MDM4. <i>Cancers</i> , 2019, 11, 1349.	4.0	6
13	A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, .	11.5	21
14	Preoperative Anti-Class III $\beta$ -Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer. <i>Translational Oncology</i> , 2018, 11, 358-365.	3.7	3
15	Identification and antitumor activity of a novel inhibitor of the NIMA-related kinase NEK6. <i>Scientific Reports</i> , 2018, 8, .	3.5	33
16	Estrogen receptor $\beta$ : Potential target for therapy in adult granulosa cell tumors?. <i>Gynecologic Oncology</i> , 2018, 150, 158-165.	3.1	27
17	Hormone receptor expression profile of low-grade serous ovarian cancers. <i>Gynecologic Oncology</i> , 2017, 145, 352-360.	3.1	35
18	Uncovering the role of nuclear Lysyl oxidase (LOX) in advanced high grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 146, 170-178.	3.1	30

#	ARTICLE	IF	PR CITATIONS
19	Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts. <i>Cancer Letters</i> , 2017, 388, 320-327.	8.8	83
20	The relevance of prelamin A and RAD51 as molecular biomarkers in cervical cancer. <i>Oncotarget</i> , 2017, 8, 94247-94258.	1.7	10
21	Targeting the hallmarks of ovarian cancer: The big picture. <i>Gynecologic Oncology</i> , 2016, 142, 176-183.	3.1	32
22	Sexual dimorphism in medulloblastoma features. <i>Histopathology</i> , 2016, 68, 541-548.	3.7	16
23	Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment. <i>Oncotarget</i> , 2016, 7, 68033-68043.	1.7	24
24	Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers. <i>Oncotarget</i> , 2016, 7, 8155-8171.	1.7	44
25	Mitochondrial estrogen receptor $\beta$ drives antiapoptotic pathways in advanced serous ovarian cancer. <i>Human Pathology</i> , 2015, 46, 1138-1146.	2.4	15
26	Letter to the Editor: Estrogen and Medulloblastoma. <i>Endocrinology</i> , 2015, 156, L6-L7.	2.6	1
27	Prognostic significance of the estrogen receptor beta (ER $\beta$ ) isoforms ER $\beta$ 1, ER $\beta$ 2, and ER $\beta$ 5 in advanced serous ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 132, 351-359.	3.1	57
28	Gender Effect in Experimental Models of Human Medulloblastoma: Does the Estrogen Receptor $\beta$ Signaling Play a Role?. <i>PLoS ONE</i> , 2014, 9, e101623.	2.4	19
29	The expression ratios of estrogen receptor $\alpha$ (ER $\alpha$ ) to estrogen receptor $\beta$ 1 (ER $\beta$ 1) and ER $\alpha$ to ER $\beta$ 2 identify poor clinical outcome in endometrioid endometrial cancer. <i>Human Pathology</i> , 2013, 44, 1047-1054.	2.4	49
30	Expression of the Glioma-Associated Oncogene Homolog 1 (Gli1) in Advanced Serous Ovarian Cancer Is Associated with Unfavorable Overall Survival. <i>PLoS ONE</i> , 2013, 8, e60145.	2.4	47
31	Clinicopathologic and Immunohistochemical Features of Ovarian Clear Cell Carcinomas in Comparison With Type I and Type II Tumors. <i>International Journal of Gynecological Pathology</i> , 2012, 31, 507-516.	1.4	26
32	Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy. <i>Current Pharmaceutical Design</i> , 2012, 18, 2734-2757.	2.4	53
33	The dualistic model of endometrial cancer: The challenge of classifying grade 3 endometrioid carcinoma. <i>Gynecologic Oncology</i> , 2012, 127, 262-263.	3.1	12
34	Prognostic role of metastasis tumor antigen 1 in patients with ovarian cancer: a clinical study. <i>Human Pathology</i> , 2012, 43, 282-288.	2.4	31
35	The estrogen receptor beta agonist diarylpropionitrile (DPN) inhibits medulloblastoma development via anti-proliferative and pro-apoptotic pathways. <i>Cancer Letters</i> , 2011, 308, 197-202.	8.8	24
36	Changes in the expression of oestrogen receptors and E-cadherin as molecular markers of progression from normal epithelium to invasive cancer in elderly patients with vulvar squamous cell carcinoma. <i>Histopathology</i> , 2011, 58, 265-275.	3.7	33

#	ARTICLE	IF	PR CITATIONS
37	Cytoplasmic expression of oestrogen receptor beta (ER $\beta$ ) as a prognostic factor in vulvar squamous cell carcinoma in elderly women. <i>Histopathology</i> , 2011, 59, 909-917.	3.7	15
38	Cytoplasmic expression of estrogen receptor beta (ER $\beta$ ) predicts poor clinical outcome in advanced serous ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 122, 573-579.	3.1	74
39	The Epithelial-Mesenchymal Transition and the Estrogen-Signaling in Ovarian Cancer. <i>Current Drug Targets</i> , 2010, 11, 474-481.	1.9	38
40	Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical pathological and immunohistochemical study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 457, 27-34.	3.0	59
41	Protective role of 17 $\beta$ -Estradiol on medulloblastoma development in <i>Patched1</i> heterozygous mice. <i>International Journal of Cancer</i> , 2010, 127, 2749-2757.	4.5	13
42	Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 68, 107-116.	2.2	54
43	Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer. <i>Carcinogenesis</i> , 2009, 30, 340-347.	2.9	68
44	Re: Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer. <i>Carcinogenesis</i> , 2009, 30, 721-721.	2.9	2
45	Antiproliferative and antiangiogenic effects of the benzophenanthridine alkaloid sanguinarine in melanoma. <i>Biochemical Pharmacology</i> , 2009, 78, 1374-1381.	5.2	93
46	New taxanes in development. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 335-347.	4.0	39
47	17 $\beta$ -Estradiol and soy phytochemicals selectively induce a type 2 polarization in mesenteric lymph nodes of ovariectomized rats. <i>Menopause</i> , 2008, 15, 718-725.	2.6	8
48	Soy Phytochemicals Decrease Nonsmall Cell Lung Cancer Growth In Female Athymic Mice3. <i>Journal of Nutrition</i> , 2008, 138, 1360-1364.	3.0	31
49	Estradiol and phytoestrogens differently influence the rodent postmenopausal mammary gland. <i>Menopause</i> , 2006, 13, 72-79.	2.6	20
50	Preclinical in vivo activity of a combination gemcitabine/liposomal doxorubicin against cisplatin-resistant human ovarian cancer (A2780/CDDP). <i>International Journal of Gynecological Cancer</i> , 2006, 16, 222-230.	2.9	13
51	Lack of stimulatory activity of a Phytoestrogen-containing soy extract on the growth of breast cancer tumors in mice. <i>Carcinogenesis</i> , 2006, 27, 1404-1409.	2.9	33
52	Characterization of the pharmacologic profile of a standardized soy extract in the ovariectomized rat model of menopause: effects on bone, uterus, and lipid profile. <i>Menopause</i> , 2005, 12, 589-600.	2.6	38
53	Thiocolchicine dimers: a novel class of topoisomerase-I inhibitors. <i>Biochemical Pharmacology</i> , 2005, 69, 113-121.	5.2	27
54	Gemcitabine: current role and future options in the treatment of ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 48, 81-88.	5.2	23

#	ARTICLE	IF	PR CITATIONS
55	Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer. <i>European Journal of Cancer</i> , 2003, 39, 2403-2410.	5.1	77
56	Bcl-2 Down-Regulation Is a Novel Mechanism of Paclitaxel Resistance. <i>Molecular Pharmacology</i> , 2003, 64, 51-58.	2.7	138
57	Second Generation Taxanes: from the Natural Framework to the Challenge of Drug Resistance. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2003, 3, 133-138.	8.0	29
58	Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin. <i>Life Sciences</i> , 2002, 70, 1447-1459.	4.7	66
59	Dietary soy modulation of biochemical parameters in DMBA-induced mammary tumors. <i>Cancer Letters</i> , 2002, 186, 43-48.	8.8	13
60	Chemoprevention of DMBA-induced mammary cancer in rats by dietary soy. <i>Breast Cancer Research and Treatment</i> , 2001, 69, 153-164.	2.4	52
61	Clinical Effects of a Standardized Soy Extract in Postmenopausal Women. <i>Menopause</i> , 2000, 7, 105-111.	2.6	204
62	Anti-tumour activity of a panel of taxanes toward a cellular model of human cervical cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 127-132.	2.2	6
63	Reproductive Effects of Dietary Soy in Female Wistar Rats. <i>Food and Chemical Toxicology</i> , 1999, 37, 493-502.	3.6	41